LIVIVO - Search results -

Search results

Result 1 - 10 of total 16

Search options

Article ; Online: Case report: ischemic priapism secondary to tinzaparin.

Purnell, Jennifer / Abdulla, Alym N

International journal of impotence research

2017 Volume 30, Issue 2, Page(s) 62–64

Abstract: Low-molecular-weight heparin (LMWH) therapy has recently been proposed as a cause of ischemic priapism. The evidence, however, remains scarce, as there are very few published cases of LMWH-induced priapism to date. The implications of such events are ... ...

Abstract	Low-molecular-weight heparin (LMWH) therapy has recently been proposed as a cause of ischemic priapism. The evidence, however, remains scarce, as there are very few published cases of LMWH-induced priapism to date. The implications of such events are significant as ischemic priapism is a medical emergency. In current clinical practice we are seeing a trend towards LMWH therapies replacing unfractionated heparin (UFH). As LMWH therapies continue to gain favor, we will potentially see more cases of LMWH-induced priapism. As such, consideration should be given to determine the underlying pathophysiology and incidence of LMWH-induced priapism. Herein, we present the case of a 33-year-old male with priapism in the setting of tinzaparin treatment.
MeSH term(s)	Adult ; Fibrinolytic Agents/adverse effects ; Fibrinolytic Agents/therapeutic use ; Heparin, Low-Molecular-Weight/adverse effects ; Heparin, Low-Molecular-Weight/therapeutic use ; Humans ; Male ; Priapism/chemically induced ; Thrombosis/drug therapy
Chemical Substances	Fibrinolytic Agents ; Heparin, Low-Molecular-Weight ; tinzaparin (7UQ7X4Y489)
Language	English
Publishing date	2017-12-08
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	1034295-3
ISSN	1476-5489 ; 0955-9930
ISSN (online)	1476-5489
ISSN	0955-9930
DOI	10.1038/s41443-017-0008-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2910: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Meta-Analysis of Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding in Patients with Cancer.

Abdulla, Alym / Davis, Wendy M / Ratnaweera, Namali / Szefer, Elena / Ballantyne Scott, Brooke / Lee, Agnes Y Y

Thrombosis and haemostasis

2020 Volume 120, Issue 4, Page(s) 702–713

Abstract: Background: Knowing the case fatality rates of recurrent venous thromboembolism (VTE) and major bleeding is important for weighing the relative risks and benefits of anticoagulation and deciding on the duration of anticoagulant therapy, but these rates ...

Abstract	Background: Knowing the case fatality rates of recurrent venous thromboembolism (VTE) and major bleeding is important for weighing the relative risks and benefits of anticoagulation and deciding on the duration of anticoagulant therapy, but these rates are uncertain in patients with cancer-associated thrombosis. Methods: We performed a systematic review and a meta-analysis to determine the incidence of recurrent VTE and major bleeding and their respective case fatality rates in patients with cancer-associated VTE. Results: Our analysis included 29 studies (15 prospective cohort studies and 14 randomized controlled trials) from 1980 to January 2019. Data from 8,000 cancer patients with 4,786 patient-years of follow-up were summarized. Rates of recurrent VTE and fatal recurrent VTE were 23.7 (95% confidence interval [CI]: 20.1-27.8) and 1.9 (95% CI: 0.8-4.0) per 100 patient-years of follow-up, respectively, with a case fatality rate of 14.8% (95% CI: 6.6-30.1%). The rates of major bleeding and fatal major bleeding events were 13.1 (95% CI: 10.3-16.7) and 0.8 (95% CI: 0.3-2.1) per 100 patient-years of follow-up, respectively, with a case fatality rate of 8.9% (95% CI: 3.5-21.1%). While the estimates of case fatality vary by anticoagulation regimen and study design, the differences between them were not statistically significant. Conclusion: In cancer patients receiving anticoagulation, the case fatality rate of recurrent VTE is higher than the case fatality rate of major bleeding. These findings may help to inform decisions regarding the management of anticoagulation in patients with active cancer and VTE.
MeSH term(s)	Anticoagulants/therapeutic use ; Clinical Trials as Topic ; Hemorrhage/epidemiology ; Hemorrhage/mortality ; Humans ; Incidence ; Mortality ; Neoplasms/epidemiology ; Neoplasms/mortality ; Recurrence ; Risk Assessment ; Venous Thromboembolism/epidemiology ; Venous Thromboembolism/mortality
Chemical Substances	Anticoagulants
Language	English
Publishing date	2020-04-14
Publishing country	Germany
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	518294-3
ISSN	2567-689X ; 0340-6245
ISSN (online)	2567-689X
ISSN	0340-6245
DOI	10.1055/s-0040-1708481
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.192: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 433: Show issues

Order via subito

Details ▾

Article ; Online: Emerging novel therapies in the treatment of castrate-resistant prostate cancer.

Abdulla, Alym / Kapoor, Anil

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

2011 Volume 5, Issue 2, Page(s) 120–133

Abstract: The treatment options for patients with castration-resistant prostate cancer (CRPC), until very recently, only included docetaxel. In the past 10 months, newly Federal Drug Administration (FDA) approved agents in the United States have shown survival ... ...

Abstract	The treatment options for patients with castration-resistant prostate cancer (CRPC), until very recently, only included docetaxel. In the past 10 months, newly Federal Drug Administration (FDA) approved agents in the United States have shown survival benefit for patients with CRPC. This review takes a closer look at these newer agents: sipuleucel-T (immune therapy) and cabazi-taxel (cytotoxic therapy). We also review the evidence supporting the FDA's approval of denosumab (bone-targeted therapy) as a treatment option for men with CRPC and bony metastases. Newer agents currently being investigated in phase III clinical trials for their potential role in metastatic CRPC are also reviewed. These agents include abiraterone (hormonal therapy), TAK-700 (hormonal therapy), MDV3100 (hormonal therapy), ipilimumab (immune therapy), zibotentan (endothelin-A receptor antagonist) and dasatinib (tyrosine kinase inhibitor). As ongoing studies using all the aforementioned agents continue to evolve, our understanding of how and where these agents fit into the treatment paradigm for patients with CRPC will become clearer.
Language	English
Publishing date	2011-04-07
Publishing country	Canada
Document type	Journal Article
ISSN	1920-1214
ISSN (online)	1920-1214
DOI	10.5489/cuaj.10160
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.

Hoiland, Ryan L / Stukas, Sophie / Cooper, Jennifer / Thiara, Sonny / Chen, Luke Y C / Biggs, Catherine M / Hay, Kevin / Lee, Agnes Y Y / Shojania, Kamran / Abdulla, Alym / Wellington, Cheryl L / Sekhon, Mypinder S

British journal of haematology

2020 Volume 190, Issue 3, Page(s) e150–e154

MeSH term(s)	Adult ; Aged ; Antibodies, Monoclonal, Humanized/therapeutic use ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/drug therapy ; Coronavirus Infections/immunology ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/virology ; Cytokines/blood ; Drug Evaluation/methods ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/immunology ; Receptors, Chimeric Antigen/therapeutic use ; Receptors, Interleukin-6/antagonists & inhibitors ; SARS-CoV-2
Chemical Substances	Antibodies, Monoclonal, Humanized ; Cytokines ; Immunosuppressive Agents ; Receptors, Chimeric Antigen ; Receptors, Interleukin-6 ; tocilizumab (I031V2H011)
Keywords	covid19
Language	English
Publishing date	2020-07-16
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80077-6
ISSN	1365-2141 ; 0007-1048
ISSN (online)	1365-2141
ISSN	0007-1048
DOI	10.1111/bjh.16961
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.182: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Buried penis: An unrecognized risk factor in the development of invasive penile cancer.

Abdulla, Alym / Daya, Dean / Pinthus, Jehonathan / Davies, Timothy

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

2012 Volume 6, Issue 5, Page(s) E199–202

Abstract: One of the documented benefits of neonatal circumcision is protection against invasive penile cancer. To date there have been a handful of published cases of invasive penile cancer in men circumcised as neonates. We report a case of a 73-year-old man, ... ...

Abstract	One of the documented benefits of neonatal circumcision is protection against invasive penile cancer. To date there have been a handful of published cases of invasive penile cancer in men circumcised as neonates. We report a case of a 73-year-old man, with a history of neonatal circumcision with no evidence of previous human papillomavirus exposure, who developed a buried penis secondary to obesity. He was diagnosed with Grade 2, pT3N0 squamous cell carcinoma of the penis. This report suggests that buried penis may pose a risk factor for the development of penile cancer despite the protective effects of neonatal circumcision. Thus periodic examination of a buried penis is warranted even in patients with no risk factors for penile cancer. A review of the literature is provided.
Language	English
Publishing date	2012-10-23
Publishing country	Canada
Document type	Journal Article
ISSN	1920-1214
ISSN (online)	1920-1214
DOI	10.5489/cuaj.11226
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.

England, James T / Abdulla, Alym / Biggs, Catherine M / Lee, Agnes Y Y / Hay, Kevin A / Hoiland, Ryan L / Wellington, Cheryl L / Sekhon, Mypinder / Jamal, Shahin / Shojania, Kamran / Chen, Luke Y C

Blood reviews

2020 Volume 45, Page(s) 100707

Abstract: A subset of patients with severe COVID-19 develop profound inflammation and multi-organ dysfunction consistent with a "Cytokine Storm Syndrome" (CSS). In this review we compare the clinical features, diagnosis, and pathogenesis of COVID-CSS with other ... ...

Abstract	A subset of patients with severe COVID-19 develop profound inflammation and multi-organ dysfunction consistent with a "Cytokine Storm Syndrome" (CSS). In this review we compare the clinical features, diagnosis, and pathogenesis of COVID-CSS with other hematological CSS, namely secondary hemophagocytic lymphohistiocytosis (sHLH), idiopathic multicentric Castleman disease (iMCD), and CAR-T cell therapy associated Cytokine Release Syndrome (CRS). Novel therapeutics targeting cytokines or inhibiting cell signaling pathways have now become the mainstay of treatment in these CSS. We review the evidence for cytokine blockade and attenuation in these known CSS as well as the emerging literature and clinical trials pertaining to COVID-CSS. Established markers of inflammation as well as cytokine levels are compared and contrasted between these four entities in order to establish a foundation for future diagnostic criteria of COVID-CSS.
MeSH term(s)	Adrenal Cortex Hormones/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Biomarkers/blood ; C-Reactive Protein/immunology ; C-Reactive Protein/metabolism ; COVID-19/immunology ; COVID-19/pathology ; COVID-19/virology ; Castleman Disease/drug therapy ; Castleman Disease/immunology ; Castleman Disease/pathology ; Clinical Trials as Topic ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/pathology ; Cytokine Release Syndrome/virology ; Ferritins/blood ; Ferritins/immunology ; Gene Expression Regulation ; Humans ; Immunologic Factors/therapeutic use ; Immunotherapy, Adoptive/adverse effects ; Interleukin-1/antagonists & inhibitors ; Interleukin-1/blood ; Interleukin-1/immunology ; Interleukin-6/antagonists & inhibitors ; Interleukin-6/blood ; Interleukin-6/immunology ; Lymphohistiocytosis, Hemophagocytic/drug therapy ; Lymphohistiocytosis, Hemophagocytic/immunology ; Lymphohistiocytosis, Hemophagocytic/pathology ; SARS-CoV-2/pathogenicity ; Signal Transduction ; COVID-19 Drug Treatment
Chemical Substances	Adrenal Cortex Hormones ; Antibodies, Monoclonal ; Biomarkers ; IL6 protein, human ; Immunologic Factors ; Interleukin-1 ; Interleukin-6 ; C-Reactive Protein (9007-41-4) ; Ferritins (9007-73-2)
Keywords	covid19
Language	English
Publishing date	2020-05-15
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	639015-8
ISSN	1532-1681 ; 0268-960X
ISSN (online)	1532-1681
ISSN	0268-960X
DOI	10.1016/j.blre.2020.100707
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2207: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome

Br J Haematol

Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #614300
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Weathering the COVID-19 storm

England, James T. / Abdulla, Alym / Biggs, Catherine M. / Lee, Agnes Y.Y. / Hay, Kevin A. / Hoiland, Ryan L. / Wellington, Cheryl L. / Sekhon, Mypinder / Jamal, Shahin / Shojania, Kamran / Chen, Luke Y.C.

Blood Reviews

Lessons from hematologic cytokine syndromes

2020 , Page(s) 100707

Keywords	Oncology ; Hematology ; covid19
Language	English
Publisher	Elsevier BV
Publishing country	us
Document type	Article ; Online
ZDB-ID	639015-8
ISSN	1532-1681 ; 0268-960X
ISSN (online)	1532-1681
ISSN	0268-960X
DOI	10.1016/j.blre.2020.100707
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Zs.A 2207: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Amelioration of COVID‐19‐related cytokine storm syndrome

Hoiland, Ryan L. / Stukas, Sophie / Cooper, Jennifer / Thiara, Sonny / Chen, Luke Y. C. / Biggs, Catherine M. / Hay, Kevin / Lee, Agnes Y. Y. / Shojania, Kamran / Abdulla, Alym / Wellington, Cheryl L. / Sekhon, Mypinder S.

British Journal of Haematology

parallels to chimeric antigen receptor‐T cell cytokine release syndrome

2020 Volume 190, Issue 3

Keywords	Hematology ; covid19
Language	English
Publisher	Wiley
Publishing country	us
Document type	Article ; Online
ZDB-ID	80077-6
ISSN	1365-2141 ; 0007-1048
ISSN (online)	1365-2141
ISSN	0007-1048
DOI	10.1111/bjh.16961
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Uh III Zs.182: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: A Meta-Analysis of Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding in Patients with Cancer

Abdulla, Alym / Davis, Wendy M. / Ratnaweera, Namali / Szefer, Elena / Ballantyne Scott, Brooke / Lee, Agnes Y. Y.

Thrombosis and Haemostasis

2020 Volume 120, Issue 04, Page(s) 702–713

Abstract	Background: Knowing the case fatality rates of recurrent venous thromboembolism (VTE) and major bleeding is important for weighing the relative risks and benefits of anticoagulation and deciding on the duration of anticoagulant therapy, but these rates are uncertain in patients with cancer-associated thrombosis. Methods: We performed a systematic review and a meta-analysis to determine the incidence of recurrent VTE and major bleeding and their respective case fatality rates in patients with cancer-associated VTE. Results: Our analysis included 29 studies (15 prospective cohort studies and 14 randomized controlled trials) from 1980 to January 2019. Data from 8,000 cancer patients with 4,786 patient-years of follow-up were summarized. Rates of recurrent VTE and fatal recurrent VTE were 23.7 (95% confidence interval [CI]: 20.1–27.8) and 1.9 (95% CI: 0.8–4.0) per 100 patient-years of follow-up, respectively, with a case fatality rate of 14.8% (95% CI: 6.6–30.1%). The rates of major bleeding and fatal major bleeding events were 13.1 (95% CI: 10.3–16.7) and 0.8 (95% CI: 0.3–2.1) per 100 patient-years of follow-up, respectively, with a case fatality rate of 8.9% (95% CI: 3.5–21.1%). While the estimates of case fatality vary by anticoagulation regimen and study design, the differences between them were not statistically significant. Conclusion: In cancer patients receiving anticoagulation, the case fatality rate of recurrent VTE is higher than the case fatality rate of major bleeding. These findings may help to inform decisions regarding the management of anticoagulation in patients with active cancer and VTE.
Keywords	thrombosis ; malignancy ; clinical trials: heparins/low-molecular-weight heparin ; clinical trials: oral anticoagulants
Language	English
Publishing date	2020-04-01
Publisher	Georg Thieme Verlag KG
Publishing place	Stuttgart ; New York
Document type	Article
ZDB-ID	518294-3
ISSN	2567-689X ; 0340-6245
ISSN (online)	2567-689X
ISSN	0340-6245
DOI	10.1055/s-0040-1708481
Database	Thieme publisher's database

In stock of ZB MED Cologne/Königswinter

Uh III Zs.192: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 433: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito